Target for Acutaas Chemicals set at ₹3,800 amidst strong growth expectations
The Indian pharma and chemicals sector is poised for growth, with Acutaas Chemicals projected to experience significant earnings expansion. Analysts forecast a target price of ₹3,800 based on a robust performance in Contract Development and Manufacturing Organizations (CDMO) and Specialty Chemicals, aiming for a Compound Annual Growth Rate (CAGR) of around 28% by FY30.
Robust Growth in CDMO Sector
The CDMO segment is forecasted to be a major driving force behind Acutaas Chemicals’ earnings growth. A remarkable CAGR of 28% from FY26 to FY30E is anticipated in this sector. A significant contributor to this growth is expected to be Daro-volumes, which analysts predict could triple to approximately 160 tonnes by FY30E. The expansion of the Nubeqa patient base, driven by successful clinical trials such as ARASTEP and DASL-HiCaP, is expected to elevate Daro-V revenues to nearly ₹1,700 crore during this period. This growth is crucial for positioning Acutaas favorably within the competitive CDMO market.
Shift Towards Specialty Chemicals
In addition to its CDMO business, Acutaas is set to capitalize on the growing demand for Specialty Chemicals. Revenue in this segment is expected to surge from ₹160 crore in FY26 to ₹730 crore by FY30E, achieving a notable CAGR of 45%. The shift towards high-value semiconductor chemicals and electrolyte additives is driving this growth. This transition aligns with global trends emphasizing technological advancements in electronics and energy storage solutions, areas where India’s chemical manufacturers are increasingly seeking a foothold.
Pharma Intermediates and Legacy Business Outlook
Within the Pharma Intermediates division, the introduction of four new CDMO molecules is anticipated to generate ₹320 crore by FY30E. This growth is accentuated by the upcoming patent expiry of Apixaban in November 2026, which is expected to provide a boost to Acutaas’ legacy pharmaceutical operations. This combination of new and established products positions the company to navigate changes in the pharmaceutical landscape effectively.
What This Means
The growth trajectories outlined for Acutaas Chemicals reflect a broader positive trend in India’s pharmaceutical and specialty chemicals sectors. With increasing investment in R&D and advancing technologies, the market dynamics are shifting favorably for companies involved in these fields. For Indian investors and market watchers, Acutaas’ ambitious growth plans signal confidence in the long-term potential of localized production capabilities and innovation within these industries. This strategic positioning is critical as India aims to strengthen its role as a global manufacturing hub for pharmaceuticals and specialty chemicals, reducing dependency on imports and enhancing export capabilities.
Frequently Asked Questions
What drives the growth of Acutaas Chemicals in the CDMO sector?
Acutaas Chemicals is experiencing growth primarily due to increasing Daro-volumes and a robust expansion of the Nubeqa patient base supported by favorable clinical trial results.
What is the expected revenue growth for Specialty Chemicals?
The Specialty Chemicals division is projected to increase revenue from ₹160 crore in FY26 to ₹730 crore by FY30E, reflecting a CAGR of 45%.
How will patent expirations affect Acutaas Chemicals?
The upcoming patent expiration of Apixaban in November 2026 is expected to support revenue growth in Acutaas’ legacy pharma business, potentially increasing market competitiveness and sales.
What is the target price set for Acutaas Chemicals?
The target price for Acutaas Chemicals is set at ₹3,800, based on a multiple of 45x projected EPS for September 2028, indicating strong future earnings potential.
